Order Article Reprints

Stein J, Anand P, Abdulmajid J, Hartz A, Unterfrauner M, Feng X, Schmieder N, Kruk L, Bojko P, Schmohl J, et al. Monitoring of (Leukemia-Specific) Immune Cells in Stages, Treatment Groups and in the Course of Disease and Therapy Contributes to Qualify Antileukemic Potential and Survival in Patients with AML. International Journal of Molecular Sciences. 2025; 26(21):10336. https://doi.org/10.3390/ijms262110336

Stein, Julian, Philipp Anand, Joudi Abdulmajid, Anne Hartz, Marianne Unterfrauner, Xiaojia Feng, Nicolas Schmieder, Linus Kruk, Peter Bojko, Joerg Schmohl, and et al. 2025. "Monitoring of (Leukemia-Specific) Immune Cells in Stages, Treatment Groups and in the Course of Disease and Therapy Contributes to Qualify Antileukemic Potential and Survival in Patients with AML" International Journal of Molecular Sciences 26, no. 21: 10336. https://doi.org/10.3390/ijms262110336

Stein, J., Anand, P., Abdulmajid, J., Hartz, A., Unterfrauner, M., Feng, X., Schmieder, N., Kruk, L., Bojko, P., Schmohl, J., Schmid, C., Filippini Velázquez, G., & Schmetzer, H. M. (2025). Monitoring of (Leukemia-Specific) Immune Cells in Stages, Treatment Groups and in the Course of Disease and Therapy Contributes to Qualify Antileukemic Potential and Survival in Patients with AML. International Journal of Molecular Sciences, 26(21), 10336. https://doi.org/10.3390/ijms262110336